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The Metabolic Role of Retinol Binding Protein 4: An Update reviews investigating thoroughly all the metabolic eff ects of RBP 4 . In this context, this article reviews the major aspects of the possible metabolic actions of RBP 4 and attempts to elucidate any resting confusion on this matter. The literature search was based on PubMed listings up to 1 August 2011.
Type 2 Diabetes and Insulin Resistance ▼ Relationship between RBP 4 and clinical and laboratory parameters of insulin resistance
Circulating RBP 4 and expression of RBP 4 mRNA in abdominal adipose tissue are increased in subjects with type 2 diabetes mellitus (T2DM) or impaired glucose tolerance (IGT), compared to subjects with normal glucose tolerance (NGT) [ 5 -7 ] . However, circulating RBP 4 and synthesis rates of RBP 4 appear to be lower in type 1 diabetes mellitus (T1DM) compared to normal, nondiabetic individuals [ 8 -11 ] . Furthermore, circulating RBP 4 Introduction ▼ Retinol-binding protein 4 (RBP 4 ), a transport protein for vitamin A, is synthesized mainly by the hepatocyte and secreted into the circulation bound to vitamin A and transthyretin [ 1 ] . Although hepatocytes are regarded as the principal source of circulating RBP 4 under normal conditions, adipose tissue has the second highest expression level [ 2 ] . The only known role of RBP 4 was that of retinol transport, until 2005, when Yang et al. [ 3 ] reported that RBP 4 is a novel adipocyte-secreted hormone that is upregulated in insulin resistant states associated with obesity, and also RBP 4 provokes insulin resistance. Since then, RBP 4 has been regarded as an adipokine, which constitutes a hormone that signals changes in fatty-tissue mass and energy status in order to control fuel usage [ 3 ] . Even more, RBP 4 has been recently proposed as an emerging cardiometabolic risk factor [ 4 ] . Although, there is a considerable number of studies focusing on the various metabolic roles of RBP 4 , the results of these studies are in some cases confl icting resulting in a discrepancy regarding some of the possible metabolic roles of RBP 4 . From this point of view, there is a need for a critical review of these studies. To the best of our knowledge, there are no strong predictor of future development of diabetes in such persons, indicating that circulating RBP 4 could serve as an early prognostic marker of the future development of T2DM in such individuals [ 6 ] . Additionally, a relationship between circulating RBP 4 and biochemical markers of carbohydrate metabolism has been reported. Specifi cally, circulating RBP 4 has been found to be positively correlated with fasting serum glucose levels (Glc), fasting serum insulin levels (Ins), glycated hemoglobin (HbA1c) [ 6 ] , and homeostasis model assessment of insulin resistance (HOMA)index [ 14 ] , and negatively correlated with GDR [ 6 , 14 , 15 ] . Furthermore, circulating RBP 4 has been reported to be positively associated with plasma glucose levels at 2 h during oral glucose tolerance test (OGTT) and negatively correlated with insulin sensitivity, as estimated by the formula of Matsuda and DeFronzo during OGTT [ 14 , 16 ] . Plasma RBP 4 levels are negatively correlated with peripheral insulin sensitivity, as estimated by the insulin-stimulated rates of glucose and fat oxidation, and with hepatic insulin sensitivity, as assessed by the diff erence in hepatic glucose production between the basal state and upon insulin infusion [ 16 ] . Notably, circulating RBP 4 has been reported to be negatively correlated with β-cell function, as estimated by the fi rst-phase disposition index (D i1 ) during an intravenous glucose tolerance test [ 16 ] . Thus, RBP 4 appears to be associated not only with insulin resistance but with β-cell function as well.
Mechanisms of RBP 4 -induced insulin resistance
It is known that skeletal muscle is the principal site of insulinstimulated glucose uptake, whereas adipose tissue takes up much less glucose under normal conditions [ 17 ] . Moreover, mice with markedly reduced GLUT4 expression in adipose tissue, but normal GLUT4 expression in muscle, are insulin resistant [ 18 ] . Adipose-specifi c deletion of GLUT4 leads to secondary defects in insulin action in muscle and liver [ 18 ] . Yang et al. showed that RBP 4 causes insulin resistance in these mice [ 3 ] . From this point of view, RBP 4 appears to constitute a factor, which is secreted by the GLUT4 -/adipocytes to induce insulin resistance in skeletal muscles [ 3 ] . The mechanism by which RBP 4 induces insulin resistance in mice was investigated by Yang et al. [ 3 ] . Specifi cally, it was found that RBP 4 causes a reduction in insulin-stimulated phosphoinositide 3-kinase [PI(3)K] activity in muscle and in insulin-stimulated tyrosine phosphorylation of insulin receptor substrate-1 (IRS1) at tyrosine residue 612, an important docking site for the p85 subunit of PI(3)K. In the same study, it was shown that RBP 4 can act directly to increase the expression of the gluconeogenic enzyme phosphoenolpyruvate kinase (Pepck) in hepatocytes and the basal glucose production and can impair the suppression of hepatic glucose production in response to insulin. Ost and Danielsson et al. gave a new insight in the mechanism of inducement of insulin resistance by RBP 4 , using subcutaneous abdominal adipose tissue from nondiabetic subjects [ 19 ] . In that study, incubation of the adipocytes with RBP 4 for 24 h reduced the insulin-induced phosphorylation of IRS1 on tyrosine and on serine 307 (phosphorylation of serine 307 by insulin results in an increased steady-state level of tyrosine phosphorylation of IRS1 in response to physiological concentrations of insulin). In adipocytes, IRS1 transmits the insulin signal further downstream via a number of signaling mediators. These mediators include protein kinase B, eventually regulating glucose uptake and other metabolic eff ects, and MAP kinase regulating the mitogenic signaling of insulin [ 20 ] . Ost and Danielsson et al.
reported that the insulin-desensitizing eff ects of RBP 4 was not transmitted further downstream to reduce insulin-sensitivity for protein kinase B phosphorylation. The fact that RBP 4 treatment did not infl uence the metabolic signaling of insulin via protein kinase B phosphorylation was attributed to the relatively short incubation period of 24 h, which may have not been long enough to elicit full-blown insulin resistance. Interestingly, RBP 4 treatment reduced the insulin sensitivity for downstream signaling to MAP kinases ERK1/2 phosphorylation. Furthermore, in this study, the incubation of isolated adipocytes from patients with T2DM with antibodies against RBP 4 restored the ability of insulin to elicit the phosphorylation of IRS1 at serine 307 and enhanced the insulin-induced phosphorylation of the MAP kinases ERK1/2. This fi nding is indicative of the ability of RBP 4 to induce insulin resistance in an autocrine or paracrine fashion, in the adipose tissue of patients with T2DM. It is noteworthy that the studies, which were performed until today, have found an inverse relationship between the expression of RBP 4 mRNA and GLUT4mRNA in visceral adipose tissue [ 3 , 7 ] . A possible explanation is that, in states of insulin resistance, where exists a downregulation of GLUT4 expression in visceral adipose tissue, there is an increased expression of RBP 4 , which may cause the insulin resistance. However, a positive relationship between RBP 4 mRNA and GLUT4mRNA in subcutaneous adipose tissue has been reported [ 16 , 21 , 22 ] or no association between them [ 7 ] . A plausible explanation for these fi ndings is that subcutaneous adipose tissue may be less important than visceral adipose tissue in determining the plasma RBP 4 levels and thus the status of insulin resistance. Furthermore, circulating RBP 4 possibly causes a compensatory upregulation of the expression of GLUT4mRNA in subcutaneous adipose tissue, as indicated by one study [ 19 ] . Therefore, RBP 4 appears to induce insulin resistance in skeletal muscle, in liver and in adipose tissue, as well.
Relationship between RBP 4 and low-grade infl ammation
It is well known that obesity is associated with low-grade infl ammation, which is causally involved in the development of insulin resistance [ 23 ] . Although there are some confl icting data, RBP 4 appears to be related with some markers of low-grade infl ammation and by this mechanism may cause, at least in part, insulin resistance. Specifi cally, a positive correlation between the expression of RBP 4 and the markers of the macrophages CD68 and MCP1 in subcutaneous abdominal adipose tissue has been reported, indicating a relationship between RBP 4 and macrophage infi ltration of adipose tissue [ 22 ] . Furthermore, serum RBP 4 levels are positively correlated with circulating infl ammatory factors, such as high-sensitivity CRP (hsCRP) and IL-6 [ 24 ] . However, the positive relationship between circulating RBP 4 and markers of low grade infl ammation should be discriminated from the negative correlation between circulating RBP 4 and factors of clinical infl ammation. The latter negative correlation is attributed to the property of RBP 4 to be a negative acute phase reactant and thus circulating RBP 4 is downregulated in illnessor injury-related infl ammation [ 25 ] . These conditions are fundamentally diff erent from obesity-related low-grade infl ammation. may explain the decrease in circulating RBP 4 in T1DM individuals compared to normal subjects [ 8 -11 ] . Consistently, untreated streptozotocin-induced diabetic rats had decreased circulating RBP 4 compared to controls, whereas insulin treated diabetic rats had increased circulating RBP 4 compared to untreated diabetic rats and lower circulating RBP 4 than controls [ 26 ] . Moreover, when visceral adipose tissue explants were cultured with recombinant insulin, there was not any change in RBP 4 secretion [ 27 ] . A plausible explanation for the above mentioned data is that, when there is not insulin defi cit, insulin treatment may not have any signifi cant impact on plasma RBP 4 levels, whereas the deprivation of the physiological actions of insulin can cause a decrease in circulating RBP 4 . Although there are some studies mentioning no change in circulating RBP 4 during thiazolidinedione treatment, circulating RBP 4 appears to decrease during thiazolidinedione treatment. Specifically, Yang et al. reported that rosiglitazone treatment of adipose GLUT4 -/mice completely normalized the elevated serum RBP 4 levels and reduced the elevated RBP 4 mRNA levels in adipose tissue [ 3 ] . Moreover, thiazolidinedione treatment of subjects with T2DM reduces circulating RBP 4 [ 28 -30 ] . However, thiazolidinedione treatment of IGT or nondiabetic subjects does not cause any change in circulating RBP 4 [ 22 , 31 ] . These results may be attributed to the fact that the study subjects did not have overt diabetes and thus the insulin sensitizing eff ects of thiazolidinediones did not fully appear. Similarly, in another study, when in the oral antidiabetic medication of subjects with T2DM 15 mg pioglitazone was added per day for 8 months, no change was found in circulating RBP 4 compared to baseline values [ 32 ] . Given the relatively low pioglitazone dose used and the fact that the patients had already been receiving antidiabetic medication, the results of this study should be interpreted with the appropriate caution. Additionally, metformin treatment has been found to cause no signifi cant change in circulating RBP 4 [ 22 , 29 ] . Furthermore, sulfonylurea treatment appears to increase plasma RBP 4 levels [ 30 , 33 ] . Moreover, circulating RBP 4 is reduced after treatment with exenatide [ 33 ] or acarbose [ 34 ] . It should be noticed that the main drawback of the majority of the above-mentioned studies is that the addition of the new antidiabetic drug was performed on patients already receiving antidiabetic medication. Thus, by this way the impact of the studied antidiabetic drug per se on RBP 4 metabolism cannot be concluded accurately.
Obesity

▼ Relationship between RBP 4 and adipose tissue
Circulating RBP 4 is elevated in obese subjects compared to lean ones [ 3 , 6 , 24 ] and in morbidly obese patients compared to lean individuals [ 35 ] . Consistently, circulating RBP 4 has been found to be positively correlated with body mass index (BMI) [ 6 , 7 , 36 ] , waist circumference (WC) [ 7 , 36 ] , and waist to hip ratio [ 37 , 38 ] , indicating that RBP 4 is related with abdominal obesity. Additionally, RBP 4 mRNA in visceral and subcutaneous abdominal adipose tissue has been shown to increase in obese patients compared to lean ones [ 7 ] . RBP 4 mRNA is elevated in visceral compared to subcutaneous adipose tissue and circulating RBP 4 is correlated more strongly with RBP 4 mRNA in visceral adipose tissue than RBP 4 mRNA in subcutaneous adipose tissue [ 7 ] . Furthermore, circulating RBP 4 is positively correlated with visceral fat area, but not with abdominal subcutaneous fat area [ 28 ] , and even more the change in circulating RBP 4 after weight loss is signifi cantly associated with the change in visceral fat area, but not with the change in subcutaneous fat area [ 39 ] . Consistently, circulating RBP 4 and RBP 4 mRNA in both visceral and subcutaneous adipose depots have been found to be increased in subjects with visceral obesity compared to subjects with nonvisceral obesity [ 7 , 28 , 40 ] . The majority of the relevant studies have found that circulating RBP 4 is positively correlated with percent trunk fat (trunk fat divided by the total body fat), rather than the absolute amount of trunk fat, the total body fat or the percent body fat [ 14 , 15 , 41 ] . From all the above-mentioned data, it can be concluded that visceral adipose tissue is possibly more important than the subcutaneous one in determining plasma RBP 4 levels and even more the ratio of the visceral to the subcutaneous adipose mass appears to be more crucial than the absolute amount of these stores. Additionally, plasma RBP 4 levels are positively correlated with liver fat [ 14 ] . Consistently, circulating RBP 4 has been found to be increased in patients with nonalcoholic fatty liver disease (NAFLD) compared to subjects who do not have NAFLD and are matched for age and gender with the patients with NAFLD [ 42 -44 ] . It should be underlined that, until today, a causal link between elevated serum RBP 4 and NAFLD beyond simple association could not be convincingly established. Thus, given the fact that the presence of NAFLD is an indicator of insulin resistance, which is associated with elevated plasma RBP 4 levels, it remains to be elucidated whether RBP 4 causes or simply refl ects NAFLD. Furthermore, circulating RBP 4 appears not to be associated with ectopic fat deposition in muscles [ 14 , 22 , 45 ] . Although many studies have shown an inverse relationship between the circulating RBP 4 and adiponectin [ 24 , 28 , 37 , 46 -51 ] , some other studies failed to fi nd any association between these adipokines [ 14 , 27 , 52 -55 ] . Notably, the major relevant studies, which included above 1 000 Asians, reported a weak negative association [ 28 , 37 , 49 ] . Apart from the above-mentioned studies, which were performed in a steady metabolic state, an inverse relationship between the induced changes of the circulating RBP 4 and adiponectin during aerobic exercise has been shown [ 56 ] . Moreover, one study reported that when isolated adipocytes from mammary adipose tissue were incubated with adiponectin, there was no signifi cant change in RBP 4 production, which may be attributed to the fact that mammary adipose tissue is more similar to subcutaneous adipose tissue than the visceral one [ 57 ] . Similarly, regarding high molecular weight (HMW) adiponectin, which is considered the most active form of the adiponectin and with the greatest clinical signifi cance [ 58 ] , an inverse relationship between the serum levels of RBP 4 and HMW adiponectin has been reported [ 50 ] . However, this relationship was not found in a population of nondiabetic subjects [ 55 ] , indicating that this association exists mainly in diabetics. It should be noticed that, given the well known causal link between adiponectin and insulin sensitivity [ 58 ] , the prevalent notion of the inducement of insulin resistance by RBP 4 is compatible with an inverse relationship between circulating RBP 4 and adiponectin. Further studies are needed to confi rm the existence of this association and to investigate whether it is causal or not.
Although the studies examining nonobese subjects in a steady metabolic state did not fi nd any relationship between circulating RBP 4 and leptin [ 14 , 46 , 53 ] , a positive association between the decrease in circulating RBP 4 and the increase in circulating leptin during a carbohydrate-restricted diet has been reported [ 59 ] . Furthermore, leptin administration to ob/ob mice reduces the expression of RBP 4 mRNA in adipose tissue [ 60 ] . On the contrary, when visceral adipose tissue explants from 10 nonobese women were cultured with recombinant leptin, there was an increase in RBP 4 secretion [ 27 ] . Notably, the studies mentioning an absence of negative association between RBP 4 and leptin included mostly nonobese subjects [ 14 , 27 , 46 , 53 ] , indicating that this relationship may exist mainly in obese subjects. Moreover, any signifi cant association between RBP 4 and resistin does not appear to exist, because the relevant studies found a very weak association between these adipokines [ 61 ] or no signifi cant association [ 46 ] . As for visfatin, a positive relationship between circulating RBP 4 and visfatin has been found in women with polycystic ovary syndrome (PCOS) [ 62 ] . Given the fact that the expression of the above-mentioned adipokines by the adipose tissue is known to be infl uenced by the presence of obesity and insulin resistance [ 63 ] , the above-mentioned relationships between RBP 4 and the rest of adipokines are possible to refl ect an indirect association between these adipokines, and not a causal link between them. Therefore, further studies are needed to investigate this topic.
RBP 4 during weight loss treatment Dietary treatment
With regard to dietary interventions, the majority of the relevant studies showed a decrease in circulating RBP 4 during hypocaloric diets [ 14 , 24 , 59 , 64 -70 ] , whereas few studies did not fi nd any change in circulating RBP 4 during such interventions [ 21 ] ( • ▶ Table 1 ). Importantly, when obese women followed a dietary intervention consisted of a 4 week very low-calorie diet (VLCD), a 2 month low-calorie diet and 3-4 months of a weight maintenance (WM) phase, plasma RBP 4 levels decreased during VLCD and subsequently gradually increased during LCD and WM phases [ 71 ] . Thus, at the end of the whole dietary intervention plasma RBP 4 levels were higher than the ones at the end of the VLCD, but lower than baseline values. A possible explanation for these results is that circulating RBP 4 is mainly infl uenced by the energy balance at a given time point, and not by the body weight per se. It is well known that weight loss treatment causes an improvement of various metabolic parameters [ 72 ] . Therefore, the changes in circulating RBP 4 during dietary interventions that result in weight loss have been associated with the improvement of various metabolic parameters, such as BMI [ 64 , 68 ] , liver fat [ 14 ] , Ins [ 24 , 68 ] , HOMA-index [ 68 ] , hsCRP, IL-6 [ 24 ] , quantitative insulin sensitivity check index (QUICKI) [ 68 ] , insulin sensitivity index of Matsuda and DeFronzo during OGTT [ 14 ] , and fractional catabolic rate (FCR) of LDL ApoB-100 [ 67 ] . The magnitude of the diet-induced decrease in circulating RBP 4 depended not only on the amount of weight loss, but also on the qualitative characteristics of the applied diet [ 59 , 70 ] . Specifically, carbohydrate-restricted diet results in greater reduction in serum RBP 4 levels compared to low-fat diet [ 59 ] . Moreover, during an application of a hypocaloric Mediterranean diet, the reduction in RBP 4 is signifi cantly greater in individuals with a higher adherence to Mediterranean dietary pattern than individuals with lower adherence, independently of the magnitude of caloric restriction or weight loss [ 70 ] .
Exercise
Regarding the exercise-induced changes in RBP 4 [ 73 ] . Furthermore, circulating RBP 4 has been shown to decrease only during a resistance exercise program, but not during aerobic exercise [ 74 ] . Although the existing studies have shown that the improvement in insulin sensitivity after resistance exercise is similar with that after aerobic exercise [ 77 ] , resistance exercise possibly has more favorable eff ects in the insulin sensitivity of skeletal muscles, as indicated by the above-mentioned more pronounced decrease in circulating RBP 4 during resistance exercise. Additionally, the exercise-induced change in RBP 4 is associ-This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
ated with the improvement in various metabolic parameters, such as GDR [ 6 ] , WC, TRG, Glc, Ins, HOMA-index and the area under the curve of glucose during OGTT (AUC glucose ) [ 56 ] .
Pharmacotherapy ( • ▶ Table 1 )
Plasma RBP 4 levels decrease after the application of a weight loss program including caloric restriction with the concomitant administration of orlistat [ 78 ] . Similar results have been found concerning sibutramine [ 39 , 79 ] . However, in the studies with orlistat and sibutramine, the noticed reduction in circulating RBP 4 may has been caused due to the caloric restriction per se. Thus, it cannot be concluded whether the administration of orlistat or sibutramine has any additive impact on the reduction of circulating RBP 4 apart from the caloric restriction. As for the impact of CB1 blockers on RBP 4 , there is only one study in humans, which was performed by our group [ 64 ] . In this study, it was found that rimonabant treatment along with a dietary intervention of obese subjects with hypertriglyceridemia for 3 months resulted in reduction of circulating RBP 4 and circulating RBP 4 was positively correlated with the percentage change of HOMA-index [ 64 ] . A possible mechanism for the rimonabantinduced reduction in circulating RBP 4 is the decrease in excretion of RBP 4 from adipose tissue, as indicated by a study showing that rimonabant treatment reduced RBP 4 mRNA expression in visceral adipose tissue of ob/ob mice [ 80 ] .
Surgical management
Most of the studies investigating the impact of bariatric surgery (gastric bypass or gastric banding) on circulating RBP 4 reported a decrease in circulating RBP 4 ( • ▶ Table 1 ), which was associated with concomitant improvements in various metabolic parameters [ 35 , 69 , 81 -84 ] . Furthermore, the reduction in circulating RBP 4 after bariatric surgery occurs mainly during periods of active weight loss, whereas the decrease in circulating RBP 4 is minimal during periods of stabilized weight loss [ 81 , 83 ] . In this aspect, these results are in agreement with the above-mentioned results in dietary intervention studies. Therefore, these results imply that RBP 4 may be considered as a dynamic marker of negative energy balance, being reduced during weight loss when a negative energy balance threshold is reached, independently of the BMI of the individuals at a given time point. Moreover, there was no diff erence in the induced changes in circulating RBP 4 between patients undergoing gastric banding and gastric bypass [ 84 ] .
Metabolic Syndrome ▼
All the previous studies have shown that circulating RBP 4 is higher in patients with metabolic syndrome (MS) than in subjects without MS [ 36 , 37 , 48 , 49 , 85 ] . Moreover, circulating RBP 4 has been associated with the number of the factors of MS [ 36 , 37 ] and also with the value of each individual constituent of MS. Specifi cally, circulating RBP 4 has been found to increase in the following states: hypertriglyceridemia, low HDL-C, hypertension, increased WC, and hyperglycemia. Among these factors, the strongest and more steady association with RBP 4 has been noticed for hypertriglyceridemia [ 36 , 37 ] , whereas the weakest and the least frequent association with RBP 4 has been found for hyperglycemia [ 37 , 85 ] .
Lipoprotein Metabolism ▼ Relationship between RBP 4 and lipid parameters
Circulating RBP 4 is positively correlated with total cholesterol (TC) [ 36 , 52 ] , low density lipoprotein cholesterol (LDL-C) [ 7 , 52 , 67 , 86 ] , triglycerides (TRG) [ 6 , 7 , 28 , 36 , 86 ] , apolipoprotein B (ApoB) [ 87 ] , small dense LDL cholesterol (sdLDL-C) [ 52 ] and negatively correlated with high density lipoprotein cholesterol (HDL-C) [ 7 , 86 ] . It should be noticed that the above-mentioned associations were found in a steady metabolic state (without any signifi cant recent change in nutrient intake and body weight). Importantly, almost all of the relevant studies reported an association of RBP 4 with TRG. Furthermore, a study by our group investigated the relationship between the changes in circulating RBP 4 and the changes in parameters of lipoprotein metabolism, during medical interventions that alter the lipoprotein profi le [ 64 ] . Specifi cally, in this study obese, hypertriglyceridemic patients followed dietary or fenofi brate treatment for 3 months. It was found that the percentage change of plasma RBP 4 levels during diet was positively correlated with the percentage change of TRG, very low density lipoprotein-cholesterol (VLDL-C), LDL-C, non-HDL-cholesterol (non-HDL-C), ApoB, and sdLDL-C. Similar associations were also reported during fenofi brate treatment.
Multiple regression analysis revealed that the percentage change of circulating RBP 4 was the best predictor of the dietinduced percentage change of ApoB. As the possible mechanism of the relationship between RBP 4 and the ApoB-containing lipoproteins was suggested the regulation of the fractional catabolic rate (FCR) of LDL ApoB100, as indicated by another study [ 67 ] . In this aspect, RBP 4 appears to be linked with the metabolic pathway, which is responsible for the diet-induced changes in ApoBcontaining lipoproteins. This link may be causal or not. To our knowledge, this matter has not been elucidated yet. Moreover, among all the associations of RBP 4 with the ApoB-containing lipoprotein subspecies, the strongest of them was the one referring to sdLDL-C. Furthermore, it was found that the percentage change of circulating RBP 4 was the best predictor of the dietinduced percentage change of sdLDL-C. The same study proposed that the mechanism linking RBP 4 with sdLDL may include not only the overproduction of sdLDL due to the increased VLDL-C, but also the regulation of delipidation cascade of triglyceride-rich LDL particles. Specifi cally, this regulation may be attributed to hepatic lipase activity, since a positive association between circulating RBP 4 and hepatic lipase activity has been previously reported [ 88 ] . Importantly, the majority of the RBP 4 -related studies have reported strong and persistent associations with the ApoB-containing lipoproteins, whereas there are much fewer studies mentioning an association of RBP 4 with the ApoAI-containing HDL-C. Possibly, the inverse relationship between RBP 4 and HDL-C can be attributed to the positive association between RBP 4 and TRG and the well known inverse relationship between TRG and HDL-C [ 89 ] . From this point of view, the relationship between RBP 4 and HDL-C may refl ect the previously reported strong association between RBP 4 and TRG. Notably, most of the studies investigating the relationship between RBP 4 and LDL-C assessed LDL-C by its indirect calculation using the Friedewald equation [LDL-C = TC − (HDL-C + TRG/5)], which is more inaccurate than the direct measurement of LDL-C, especially in subjects with considerable hypertriglyceridemia [ 90 , 91 ] . Moreover, studies assessing LDL-C by its direct measurement with lipoprotein electrophoresis found quite steady and strong associations This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
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Christou GA et al. between RBP 4 and LDL-C [ 52 , 64 , 86 ] . Thus, the absence or the weakness of the association between RBP 4 and LDL-C, which has been reported in some studies, may not be true. Furthermore, to the best of our knowledge, there is only one study investigating the association of circulating RBP 4 with sdLDL-C, in a steady metabolic state [ 52 ] . This study found a positive relationship between circulating RBP 4 and sdLDL-C, in a population of young women. Notably, all these women had normal TRG. Given the fact that small dense LDL particles predominate in states of hypertriglyceridemia [ 92 ] , the positive relationship between circulating RBP 4 and sdLDL-C needs to be confi rmed in hypertriglyceridemic subjects, as well.
Although, there are some clinical studies mentioning no association between circulating RBP 4 and serum free fatty acids (FFAs) levels [ 14 , 45 ] , RBP 4 +/and RBP 4 -/mice have decreased circulat-
ing FFAs compared to wild type mice [ 3 ] . A possible explanation is that RBP 4 may be involved in the regulation of FFA metabolism, but RBP 4 alone does not appear to be signifi cant enough to determine serum FFA levels, at least in normal states.
RBP 4 levels and hypolipidemic agents ( • ▶ Table 1 )
Statins cause a signifi cant reduction of circulating RBP 4 [ 93 ] or not change [ 31 ] or a nonsignifi cant trend for decrease [ 94 , 95 ] , which may be attributed either to the not long enough period of statin administration to induce changes in circulating RBP 4 [ 94 ] or to the relative low statin dose used [ 95 ] . The mechanism underlying the potential statin-induced reduction of circulating RBP 4 may involve the statin-LDL lowering eff ect, given the previously reported relationship between RBP 4 and LDL metabolism [ 64 , 67 ] .
Fibrates decrease RBP 4 levels [ 64 , 93 , 96 ] , possibly due to the fenofi brate-induced suppression of RBP 4 mRNA levels, in adipose tissue [ 96 ] . Furthermore, a study by our group [ 64 ] investigated the impact of 3-month fenofi brate treatment on plasma RBP 4 levels, in obese hypertriglyceridemic patients. Specifi cally, this study elucidated that fenofi brate caused an increase in serum creatinine and a decrease in renal excretion of proteins. Given the fact that, RBP 4 belongs to low molecular weight proteins that are traced in urine samples [ 97 ] , the early rise in circulating RBP 4 during the fi rst month of fenofi brate treatment was attributed to the fenofibrate-induced decrease in renal clearance of RBP 4 . Subsequently, the fall in circulating RBP 4 during the following 2 months resulted from the metabolic action of fenofi brate. Circulating RBP 4 decreases after combination treatment of diet and cholestyramine [ 93 ] . However, in this case, it can not be excluded that the diet caused the decrease in circulating RBP 4 , whereas the cholestyramine per se did not have any signifi cant impact on circulating RBP 4 . It has been reported that ezetimibe treatment does not infl uence plasma RBP 4 levels [ 98 ] .
Cardiovascular Disease ▼
Circulating RBP 4 has been found to be associated with some measures of subclinical cardiovascular disease (CVD). Specifi cally, plasma RBP 4 levels have been shown to be positively correlated with the echocardiographically measured left ventricular wall thickness and carotid intima-media thickness (IMT) and negatively correlated with the fl ow-mediated dilatation (FMD), as a measure of endothelial function, and with the gray scale median in IMT (GSM-IMT) (a lower value of GSM-IMT corresponds to a higher fat content of the carotid vessel wall) [ 53 , 99 -101 ] . Consist-ently, the presence of clinical arteriosclerosis (defi ned as the presence of at least one of the following: coronary heart disease, stroke, or peripheral vascular disease) is associated with higher circulating RBP 4 and this is also observed when every vascular disease category is considered separately [ 4 ] . Similarly, circulating RBP 4 has been associated with any prior cerebrovascular disease and with any prior hospitalization for CVD [ 36 ] . Moreover, the circulating RBP 4 of patients who had fatal or nonfatal coronary artery disease during follow-up is higher compared to that of the individuals who remained free of cardiovascular disease during follow-up [ 87 ] . Furthermore, acute or subacute cerebral infarction has been associated with elevated circulating RBP 4 [ 50 ] . Although a well-documented relationship exists between RBP 4 and CVD, it remains to be elucidated whether RBP 4 is causally involved in the development of CVD.
Regarding the possible mechanism underlying the association of RBP 4 with CVD, in subjects with T2DM, circulating RBP 4 is positively associated with the soluble adhesion molecules sICAM-1 and sE-selectin, indicating that circulating RBP 4 may be responsible for the development of vascular complications in T2DM [ 53 ] . Moreover, given the well known strong association of RBP 4 with the atherogenic ApoB-containing lipoproteins and especially with triglycerides, this relationship appears to be a plausible mechanism linking at least in part RBP 4 with CVD. Indeed, the association between circulating RBP 4 and CVD becomes insignifi cant after adjustment for TRG [ 36 , 87 ] . Furthermore, the negative association between mean IMT and retinol/RBP 4 ratio persists even after adjustment for established cardiovascular risk factors [ 101 ] . Thus, given that the retinol/RBP 4 ratio indicates the saturation of RBP 4 with retinol, retinol-free RBP 4 (apo-RBP 4 ) may have a specifi c role in the development of atherosclerosis.
The Impact of Renal Function on Circulating RBP 4
It is well known that RBP 4 is fi ltered through the glomerulus and subsequently is reabsorbed into the proximal tubular cells [ 102 , 103 ] . Moreover, RBP 4 belongs to low molecular weight proteins that are traced in urine samples [ 97 ] . From this point of view, plasma RBP 4 levels are positively correlated with serum creatinine and degree of albuminuria, negatively correlated with Glomerular Filtration Rate (GFR) and they generally increase in renal dysfunction [ 104 , 105 ] .
Measurement of RBP 4
Regarding the procedure of measurement circulating RBP 4 , the majority of the relevant studies have used the ELISA method and the rest have implied quantitative Western blotting or nephelometry. ELISA method has been reported to underestimate circulating RBP 4 in diabetic subjects, due to assay saturation, and quantitative Western blotting has been proposed as the most reliable method for assaying circulating RBP 4 [ 106 ] . However, the procedure of quantitative Western blotting is too laborious, time-consuming and it needs the appropriate experience. Thus, it is not practical for studies using a big number of samples. Furthermore, ELISA results are similar and are strongly associated with Western blotting results [ 22 , 83 , 107 , 108 ] and ELISA method is much easier and more quicker than Western blotting. From this point of view, ELISA method appears to be a practical and respectable enough choice in measuring circulating RBP 4 . Another aspect, which should be taken into account in the measurement of circulating RBP 4 , is whether there have been used plasma or serum samples, because plasma anticoagulants may This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
cause spurious results [ 106 ] . However, manufacturers usually advocate the use of either serum or plasma samples.
Conclusions ▼ RBP 4 appears to be an adipokine, which induces insulin resistance and is possibly involved in the pathogenesis of the metabolic complications of obesity. Importantly, the existence of a close association of the RBP 4 both with the atherogenic ApoBcontaining lipoproteins and CVD has been reported. Notably, an important limitation of some of the RBP 4 -related studies is that they included patients who received drugs, known to infl uence circulating RBP 4 , such as oral antidiabetic drugs and hypolipidemic agents, or patients in conditions infl uencing circulating RBP 4 , such as renal or hepatic damage. Furthermore, regarding the associations of RBP 4 with some metabolic parameters, there are no studies investigating the aspect of causality. In other words, the establishment of the various potential metabolic roles of RBP 4 demands the demonstration that RBP 4 is causally linked with the above-mentioned metabolic parameters. Therefore, further carefully planned studies are needed, focusing on the investigation of whether RBP 4 constitutes a causal metabolic factor and on the molecular mechanism of action of RBP 4 .
